Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.

The presence of an ESR1 mutation in the plasma also showed a trend towards enrichment in patients with luminal A status determined by PAM50 algorithm 22 , as 41.4% of patients with PAM50 defined luminal A tumours had ESR1 mutations compared with 31.8% of patients with luminal B tumours ( Table 1 and Supplementary Table 1 ).

also in 53,322 other papers